Company intelligence / Profile preview

Mycenax Biotech Inc.

Ownership: Private
Employees: ~387
Development stage: Commercial

Overview

Mycenax has successfully launched TuNEX® in Taiwan since 2018. LusiNEX® completed Phase I and was planned to enter Phase III as of late 2019. The trastuzumab biosimilar was in early research with no recent reported development as of January 2022. The company provides end-to-end CDMO services from early-stage development to GMP manufacturing for a wide range of biologics.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodiesrecombinant proteinsvaccinessmall peptidesfusion proteinsbi/multi-specific antibodiesADCs/PDCs (antibody-drug conjugates/peptide-drug conjugates)plasmid DNAcell therapy products
Industry: Biotech

Partnerships

European pharmaceutical company for biologics developmentJapanese pharmaceutical company for biologics developmentAustralian pharmaceutical company for biologics development

Beyond the preview

Go deeper on Mycenax Biotech Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycenax Biotech Inc..

Explore the full profile